About Bolder Science

Our mission is to provide healthcare professionals with unbiased clinical research information, easily.

Currently, you can access the following clinical trials being conducted worldwide:

339,504 studies
in
214 countries
Clinical trial information and results are updated daily from ClinicalTrials.gov. The latest data update was conducted on 06/01/2020.
This website is for US healthcare professionals

Log In to Bolder Science

or

Don't have an account? Sign Up

Please enter your email address.

You will receive a link to create a new password via email.

Log In

Create an Account

or
(optional) ?

Welcome, !

Please complete the following 4 questions to ensure you receive the information that best suits your needs.

Clinical Trials of Interest

When I’m looking for information on clinical trials, I usually am interested in...

finding clinical trials in which to enroll my patients

Rarely Often

finding newly launched clinical trials (for all phases)

Rarely Often

updates on status changes for clinical trials

Rarely Often

pipeline molecules

Rarely Often

Drug Interventions

Enter up to 3 drug interventions you are currently interested in:

Clinical trial information and results are updated daily from ClinicalTrials.gov. The latest data update was conducted on 06/01/2020.

Perioperative Therapy for Resectable and Borderline-Resectable Pancreatic Adenocarcinoma With Molecular Correlates

Clinicaltrials.gov identifier NCT02723331

Recruitment Status Recruiting

First Posted March 30, 2016

Last update posted November 20, 2019

Study Description

Brief summary:

The objective of this study is to estimate the R0 resection rate in patients with Resectable Pancreatic Ductal Adenocarcinoma (R-PDAC) as well as those with Resectable Pancreatic Ductal Adenocarcinoma (BR-PDAC) independently in response to neoadjuvant sequential therapy of combination nab-paclitaxel and gemcitabine followed by stereotactic body radiotherapy (SBRT).

  • Condition or Disease:Pancreatic Cancer
    Pancreatic Adenocarcinoma
    Pancreas Ductal Adenocarcinoma
  • Intervention/Treatment: Drug: Nab-paclitaxel and gemcitabine for R-PDAC Patients
    Drug: Nab-paclitaxel and gemcitabine for BR-PDAC Patients
  • Phase: Phase 2
Detailed Description

Patients in both cohorts will receive a total of 3 cycles of neoadjuvant combination chemotherapy of nab-paclitaxel and gemcitabine, followed by re-staging CT scan, if re-staging CT does not show evidence of metastatic disease. Patients will receive SBRT and definitive surgical resection. Subsequently, patients will receive 3 cycles of adjuvant combination chemotherapy of nab-paclitaxel and gemcitabine. Each cycle of combination chemotherapy will be a total of 4 weeks. Patients will be evaluated for response at completion of the 3 cycles of neoadjuvant combination chemotherapy with CT scans of chest, abdomen and pelvis. Patients will undergo surveillance CT scan at 3-month intervals until evidence of disease progression.

Study Design
  • Study Type: Interventional
  • Estimated Enrollment: 50 participants
  • Allocation: Non-Randomized
  • Intervention Model: Parallel Assignment
  • Masking: None (Open Label) ()
  • Primary Purpose: Treatment
  • Official Title: Perioperative Therapy for Resectable Pancreatic Adenocarcinoma and Borderline Resectable Pancreatic Adenocarcinoma With Molecular Correlates
  • Actual Study Start Date: December 2016
  • Estimated Primary Completion Date: August 2020
  • Estimated Study Completion Date: May 2021
Arms and interventions
Arm Intervention/treatment
Experimental: Nab-paclitaxel/Gemcitabine for R-PDAC
Nab-paclitaxel and gemcitabine, for R-PDAC patients enrolled in this trial, will be given in combination as neoadjuvant combination chemotherapy, followed by SBRT. This is will be followed up by surgical resection and an additional combination chemotherapy of nab-paclitaxel and gemcitabine as adjuvant chemotherapy.
Drug: Nab-paclitaxel and gemcitabine for R-PDAC Patients
Nab-paclitaxel and gemcitabine, for R-PDAC patients, will be given in combination as neoadjuvant and adjuvant chemotherapy. Nab-paclitaxel will be administered by IV infusion at a dose of 125 mg/m2 over 30 minutes on Days 1, 8, and 15 of every 28-day cycle. Gemcitabine will be administered by IV infusion, immediately after the administration of nab-paclitaxel, at a dose of 1000 mg/m2 over 30 minutes on Days 1, 8 and 15 of every 28-day cycle.
Experimental: Nab-paclitaxel/Gemcitabine for BR-PDAC
Nab-paclitaxel and gemcitabine, for BR-PDAC patients enrolled in this trial, will be given in combination as neoadjuvant combination chemotherapy, followed by SBRT. This is will be followed up by surgical resection and an additional combination chemotherapy of nab-paclitaxel and gemcitabine as adjuvant chemotherapy.
Drug: Nab-paclitaxel and gemcitabine for BR-PDAC Patients
Nab-paclitaxel and gemcitabine, for BR-PDAC patients, will be given in combination as neoadjuvant and adjuvant chemotherapy. Nab-paclitaxel will be administered by IV infusion at a dose of 125 mg/m2 over 30 minutes on Days 1, 8, and 15 of every 28-day cycle. Gemcitabine will be administered by IV infusion, immediately after the administration of nab-paclitaxel, at a dose of 1000 mg/m2 over 30 minutes on Days 1, 8 and 15 of every 28-day cycle.
Outcome Measures
  • Primary Outcome Measures: 1. R0 resection rates in each cohort as measured by macroscopically complete tumor removal with negative microscopic surgical margins [ Time Frame: surgery ]
    R0 resection rates will be measured in patients with resectable PDAC and with patients with borderline-resectable PDAC, independently in response to neoadjuvant sequential therapy of combination of nab-paclitaxel and gemcitabine and SBRT, as perioperative therapy. R0 resection is determined by macroscopically complete tumor removal with negative microscopic surgical margins in the bile duct, pancreatic parenchyma, and superior mesenteric artery (SMA).
  • Secondary Outcome Measures: 1. Number of participants with treatment related adverse events as assessed by CTCAE v.4.03 [ Time Frame: 24 months ]
  • 2. Number of participants with progression-free occurence [ Time Frame: Up to 5 years ]
    The progression-free survival (PFS) will be assessed for all participants using Response Evaluation Criteria in Solid Tumors (RECIST v1.1).
  • 3. Number of participants with disease recurrence [ Time Frame: Up to 5 years ]
    Disease-free survival will be assessed for all participants using Response Evaluation Criteria in Solid Tumors (RECIST v1.1).
Eligibility Criteria
  • Ages Eligible for Study: 18 to 101 Years (Adult, Older Adult)
  • Sexes Eligible for Study: All
  • Accepts Healthy Volunteers: No
Criteria

Inclusion Criteria:

1. Histologically confirmed resectable or borderline resectable pancreatic
adenocarcinoma.

2. No evidence of distant metastasis representing stage IV metastatic disease.

3. R-PDAC: No evidence of distant metastasis and tumor mass showing no extension to
superior mesenteric artery (SMA) and hepatic artery. There must be a clearly defined
fat plane between SMA and celiac axis. Patent superior mesenteric vein (SMV/portal
vein (PV) with no distortion of venous architecture.

4. BR-PDAC: defined as localized PDAC with 1 or more of the following features: a) an
interface between the primary tumor and superior mesenteric vein (SMV)-portal vein
(PV) measuring 180o or greater of the circumference of the vein wall, and/or b)
short-segment occlusion of the SMV-PV with normal vein above and below the level of
obstruction that is amenable to resection and venous reconstruction and/or c)
short-segment interface of any degree between tumor and hepatic artery with normal
artery proximal and distal to the interface that is amenable to resection and arterial
reconstruction and/or d) an interface between the tumor and SMA or celiac trunk
measuring less than 180o of the circumference of the artery wall.

5. Age > 18 years old

6. Eastern Cooperative Oncology Group (ECOG) performance status of 0 or 1

7. Patients must have adequate bone marrow function:

- Platelets >100,000 cells/mm3

- Hemoglobin > 9.0 g/dL

- Absolute Neutrophil Count > 1,500 cells/mm3

8. Patients must have adequate liver function:

- aspartate aminotransferase (AST) and Alanine Aminotransferase (ALT) < 2.5 X upper limit of normal - Alkaline phosphatase < 2.5 X upper limit of normal, unless bone metastasis is present in the absence of liver metastasis - Total bilirubin < 1.5 mg/dL 9. Patients must have adequate renal function: creatinine 50 mL/min calculated using the Cockcroft-Gault
equation.

10. Women of childbearing potential and sexually active males must use an effective
contraception method during treatment and for three months after completing treatment.

11. Negative serum or urine β-human chorionic gonadotropin (hCG) pregnancy test at
screening for patients of childbearing potential.

12. Patients must have grade 1).

8. Patients with clinically significant cardiac disease (New York Heart Association
Classification III or IV and cardiac arrhythmias not well controlled with medication),
or myocardial infarction within the previous six months.

9. Serious, uncontrolled, concurrent infection(s) requiring antibiotics.

10. Pregnant or breastfeeding women: positive pregnancy test within 7 days of starting
treatment.

11. Treatment for other carcinomas within the last five years, except cured non-melanoma
skin and treated in-situ cervical cancer.

12. Participation in any investigational drug study within 4 weeks preceding the start of
study treatment.

13. Patients with external biliary drains.

Contacts and Locations
Contacts

Contact: Chalaunda Scott 720-848-1234 chalaunda.scott@ucdenver.edu

Locations

United States, Arizona
Mayo Clinic Hospital
Scottsdale

United States, Arizona
University of Arizona
Tucson

United States, Colorado
University of Colorado Cancer Center
Aurora

United States, New York
New York University
New York

Sponsors and Collaborators

Academic Thoracic Oncology Medical Investigators Consortium

Celgene Corporation

Criterium, Inc.

University of Colorado, Denver

Investigators

Principal Investigator: Wells Messersmith, MD University of Colorado, Denver

More Information
  • Responsible Party: Academic Thoracic Oncology Medical Investigators Consortium
  • ClinicalTrials.gov Identifier: NCT02723331 History of Changes
  • Other Study ID Numbers: 15-0150.cc
  • First Posted: March 30, 2016 Key Record Dates
  • Last Update Posted: November 20, 2019
  • Last Verified: November 2019
  • Individual Participant
    Data (IPD) Sharing
    Statement:
  • Plan to Share IPD: No
  • Keywords provided by Academic Thoracic Oncology Medical Investigators Consortium: Stereotactic Body Radiation Therapy
    Perioperative Therapy
    Resectable Pancreas Ductal Adenocarcinoma
    Borderline Resectable Pancreas Ductal Adenocarcinoma
    Nab-paclitaxel
    Abraxane
    Gemcitabine
    Neoadjuvant Therapy
    Adjuvant Therapy
  • Additional relevant MeSH terms: Adenocarcinoma